Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Rates of noncirrhotic portal hypertension have ranged from 1%[Maida 2006] to 8% of HIV-infected patients[Mallet 2007]
  • No single etiology or characteristic histologic finding has been identified to explain noncirrhotic portal hypertension in HIV-infected patients without HBV or HCV infection
  • FDA published an alert about the risk of noncirrhotic portal hypertension in patients taking didanosine and added new information to the prescription label[FDA 2010]

    Action required

    Keywords: Hepatic Complications, Mitochondrial Disorders, Special Populations

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.